Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.Synonyms
- Anti-Extractable Nuclear Antigens (ENA) 6 Plus Anti-Dense Fine Speckled 70 Antibodies Profile
Test Includes
Anti-DFS70; Anti-Sm; Anti-U1 RNP; Anti-Ro (SS-A); Anti-La (SS-B); Anti-Scl-70; Anti-Jo-1
Expected Turnaround Time
14 - 21 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
For more information, please view the literature below.
Antinuclear Antibodies Initial Screening Profiles Flyer
Specimen Requirements
Specimen
Serum
Volume
3 mL
Minimum Volume
1.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 7 days |
Refrigerated | 14 days |
Frozen | 60 days |
Freeze/thaw cycles | Stable x1 |
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic, icteric, non-serum specimen types
Test Details
Use
Anti-ENA6 Plus DFS70 is designed to facilitate the proper triage of patients with positive Anti-Nuclear Antibodies (ANA) by identifying those most likely to benefit from a rheumatology specialist. It detects the novel Anti-DFS70 along with 6 other clinically useful autoantibodies to ENA, which may help identify systemic lupus erythematous (SLE), mixed connective tissue disease (MCTD), Sjogren's, systemic sclerosis, and idiopathic inflammatory myopathy (IIM). Positive Anti-DFS70 antibodies in isolation may help identify individuals who do not have an AARD (ANA-associated rheumatic disease), especially in the absence of significant clinical findings.
Anti-DFS70 Abs confer a likelihood ratio for the absence of systemic autoimmune rheumatic disease of 10.9 and are detectable in 2% to 22% of healthy individuals and in less than 1% of patients with AARD.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
See individual test components.
References
Conrad K, Röber N, Andrade LE, Mahler M. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clin Rev Allergy Immunol. 2017 Apr;52(2):202-216.27350273
Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS One. 2014 Apr 4;9(4):e93812.24705829
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520316 | Anti-DFS70 Ab | Units | 95129-3 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520216 | Anti-Sm Ab (RDL) | Units | 11090-8 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520217 | Anti-U1 RNP Ab (RDL) | Units | 57662-9 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520218 | Anti-Ro (SS-A) Ab (RDL) | Units | 33569-5 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520225 | Anti-La (SS-B) Ab (RDL) | Units | 45142-7 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520221 | Anti-Scl-70 Ab (RDL) | Units | 26975-3 | |
| 520301 | Anti-ENA6 Plus DFS70Ab Profile | 520259 | Anti-Jo-1 Ab (RDL) | Units | 35333-4 |
| Reflex Table for Anti-Scl-70 Ab (RDL) | ||||||
|---|---|---|---|---|---|---|
| Order Code | Order Name | Result Code | Result Name | UofM | Result LOINC | |
| Reflex 1 | 520341 | Repeat Anti-Scl-70 | 520341 | Repeat Anti-Scl-70 | 5348-8 | |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf